Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 5, 2014

View Archived Issues

GeNeuro and Servier to develop drug addressing a causal factor of multiple sclerosis

Prothena reports phase I/II data for NEOD-001 in AL amyloidosis and initiates phase III trial

Phase III control patients with newly diagnosed GBM cleared to receive Novocure's TTFields

Roche to acquire Ariosa Diagnostics

ADMA's phase III study of RI-002 for primary immune deficiency disease meets primary endpoint

BeyondSpring Pharmaceuticals to conduct phase III trial of plinabulin in NSCLC

Bayer files for E.U. approval of BAY-81-8973 for hemophilia A

Evidence of autoimmune predisposition in Down Syndrome

Interim phase I/II results for TPI-287 plus bevacizumab in patients with recurrent GBM

Array BioPharma regains rights to binimetinib from Novartis

Results for anacetrapib from phase III REALIZE study

Phase II results presented for ARC-520 in patients with chronic HBV infection

Anti-CD19 MAb granted orphan status for diffuse large B-cell lymphoma

The University of Szeged divulges inhibitors of Abeta neurotoxicity

Janssen R&D Ireland reports development of TLR agonists

MedoLution presents new BTK/EGFR inhibitors

U.S. researchers present novel inhibitors of protozoal CDPK1

DPI-289, a dual delta agonist/mu antagonist, shows promise in models of Parkinson's disease

Michael J. Fox Foundation for Parkinson's Research awards grant to Gismo Therapeutics

FDA approves ruxolitinib for polycytemia vera

TxCell initiates phase IIb study of Ovasave for refractory Crohn's disease

PTC Therapeutics launches Translarna for nonsense mutation DMD

FDA gives tentative approval to abacavir/lamivudine pediatric formulations

Armgo Pharma and Servier advance ARM-210 into clinical program for DMD

FDA grants Cellectar's [131I]CLR-1404 orphan drug designation for multiple myeloma

First subject dosed in phase I study of prime-boost regimen of Ebola candidate vaccines

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...